Experimental Treatment for Lymphoproliferative Diseases
common.study.values.description
“A Study of the Safety and Efficacy of EBV Specific T-cell Lines”
This study evaluates the safety and efficacy of EBV-specific T-cell lines to treat patients suffering from high EBV viral titers not responding to standard of care therapies and to treat EBV-related lymphoma. The study will recruit 6 patients to receive autologous T cells or a T cell line derived from the patient's allogeneic donor (in the case of stem cell transplant recipients), and 6 patients to receive a T-cell line prepared from a matched or partially matched related donor.
common.study.values.location
participant.ui.study.affiliations-map.online-study.header-virtual
participant.ui.study.affiliations-map.online-study.text
common.study.values.methods
common.study.methods.has-drugs-no
common.study.methods.is-healthy-no
Biological - Group A
Peptide-stimulated T cells 2 x 10^7/m^2
Biological - Group B
Peptide-stimulated T cells per dose-escalation protocol
participant.views.study.view.additional
participant.views.study.view.scientific-title
A Phase I/II Open-label Study of the Safety and Efficacy of Epstein-Barr Virus Specific T-cell Lines for the Treatment of EBV Infection or EBV-related Lymphoproliferative Diseases
common.study.values.clinical-trial-id
NCT02580539
participant.views.study.view.id
5eVoOa
